METHOD OF SELECTING THERAPY OF CHRONIC INFLAMMATORY DISEASES OF EYE SURFACE BASED ON CONTROLLED POTENTIATION OF EXUDATIVE REACTION BY MEANS OF MECHANICAL OR IMMUNE IMPACT Russian patent published in 2011 - IPC A61F9/00 A61K38/21 A61P27/02 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, and can be used in treatment of chronic inflammatory diseases of eye surface. For this purpose, first, smears of discharge from conjunctival cavity, stained by Gram are tested, and clinical manifestations of eye surface inflammation are estimated. In case of detecting slightly hyperemic conjunctriva, randomly located single follicles, muco-purulent discharge or grayish-white discharge from eyes, fine-point subepithelial infiltrates on cornea, low leukocytosis - to 15 in the field of view, instilled is leukocyte interferon - a-interferon 1000 IU in dose 1 drop into each eye in the morning and from 18 o'clock each hour: 18, 19, 20, before going to bed with single dilution on the eve of test aimed at detection of infectious agent. In case of detecting slightly hyperemic conjunctriva, single follicles, purulent discharge from eyes, expressed changes of cornea in form of epithelium defects, medium leukocytosis - 30-40 in the field of view; instilled is leukocyte interferon 8000 IU in dose 1 drop into each eye in the morning and from 18 o'clock each hour: 18, 19, 20, before going to bed with single dilution on the eve of the test. In case of detecting considerably hyperemic conjunctriva, single follicles, purulent discharge from eyes, boundary keratitis or subepithelial infiltrates, high leukocytosis - 40-100 in the field of view; instilled is α2B recombinant interferon 10000 IU in dose 1 drop into each eye in the morning and from 18 o'clock each hour: 18, 19, 20, before going to bed with single dilution on the eve of the test. In case of detecting slightly hyperemic conjunctriva, numerous follicles, grayish-white discharge from eyes, subepithelial infiltrates, medium leukocytosis - 30-40 in the field of view; 2 hours before material sampling for carrying out the test, instilled is α2B recombinant interferon 1000000 IU in dose 1 drop, 2 times into each eye. In case of detecting slightly hyperemic conjunctriva, numerous follicles, muco-purulent or purulent discharge from eyes, boundary keratitis, medium leukocytosis - 30-40 in the field of view; 3 hours before material sampling for carrying out the test, performed are injections under conjunctiva of 0.2 ml of α2B recombinant interferon 1000000 IU. In case of detecting hyperemia of eye-lid edges, scales and purulent crusts on eye-lids, friable and hyperemic conjunctiva, blocking of tarsal glands, single follicles in form of beads, purulent discharge from eyes, absence of defects on cornea, medium leukocytosis - 30-40 in the field of view; immediately before carrying out the test, massage of eye lids with glass stick is carried out. After that diagnostic test is perfomed, aimed at detection of infectious agent of vision organ, for which purpose carried out is test of smears of discharge from conjunctival cavity and scrapes from cornea mucosa and eye conjunctiva, stained by Romanovsky-Giemsa and by Gram, on the basis of detected infectious agent is accepted together with atiotropic antibiotic therapy. Of gonorrhea of vision organ is detected, introduced is leukocyte interferon 8000 UI/ml or α2B recombinant interferon 10000 IU. In case of ophthalmic chlamydiosis introduced is leukocyte interferon 1000 IU in form of drop instillations or α2B recombinant interferon -1000000 IU in form of injection under conjunctiva. In case if mycoplasmas are detected, α2B recombinant interferon - 1000000 IU is introduced in form of injection under conjunctiva. If herpetic cells are detected in scrapes from mucosa - α2B recombinant interferon - 1000000 IU in form of injection under conjunctiva. If candidas are detected, leukocyte interferon in dose 1000 IU is introduced in form of drop instillations. If ureaplasma is detected, α2B recombinant interferon - 1000000 IU is introduced in form of injection under conjunctiva. If mixed-infection is detected, α2B recombinant interferon - 10000 IU and α2B recombinant interferon -1000000 IU are introduced in form of injection under conjunctiva.

EFFECT: method makes it possible to increase efficiency of performed pathogenetic therapy due to fast and exact verification of infectious agent.

1 tbl, 3 ex